Format

Send to

Choose Destination
Cancer J. 2017 Mar/Apr;23(2):125-130. doi: 10.1097/PPO.0000000000000247.

Applied Cancer Immunogenomics: Leveraging Neoantigen Discovery in Glioblastoma.

Author information

1
From the *Division of Oncology, Department of Medicine, †The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital, ‡Center for Human Immunology and Immunotherapy Programs, and Departments of §Neurological Surgery and ∥Pathology and Immunology, Washington University School of Medicine, St Louis, MO.

Abstract

Glioblastoma (GBM) remains a significant cause of cancer-related mortality in pediatric and adult patients with limited treatment options. Immunotherapy represents a promising new therapeutic approach in many solid and hematologic malignancies, including GBM, although only a subset of patients responds clinically. Thus, current efforts are focused on identifying patients most likely to benefit from immune-based therapies. The cancer immunogenomics approach identifies candidate neoantigens from genomics information and represents a potentially exciting new space in precision neuro-oncology. In this review, we discuss the role of neoantigens in GBM both as predictive biomarkers and as targets of immunotherapy.

PMID:
28410300
PMCID:
PMC5605294
DOI:
10.1097/PPO.0000000000000247
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center